Atara Biotherapeutics (ATRA) Cash from Investing Activities (2014 - 2025)

Atara Biotherapeutics' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $8.4 million for Q4 2025.

• Quarterly Cash from Investing Activities rose 150.0% year-over-year to $8.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $949000.0 (down 91.46% YoY) and the FY2025 annual result came in at $18.1 million, up 110.44% from the prior year.
• Cash from Investing Activities was $8.4 million for Q4 2025 at Atara Biotherapeutics, up from -$2.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $70.4 million in Q3 2023 and bottomed at -$24.3 million in Q4 2021.
• A 5-year average of $18.8 million and a median of $11.7 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 4899.75% — and 2025, when it sank 170.46%.
• Atara Biotherapeutics' Cash from Investing Activities stood at -$24.3 million in 2021, then soared by 310.57% to $51.2 million in 2022, then slumped by 80.58% to $9.9 million in 2023, then slumped by 66.05% to $3.4 million in 2024, then surged by 150.0% to $8.4 million in 2025.
• Business Quant data shows ATRA's Cash from Investing Activities at $8.4 million in Q4 2025, -$2.4 million in Q3 2025, and -$5.1 million in Q2 2025.